Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT ID: NCT00137020
Last Updated: 2021-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
294 participants
INTERVENTIONAL
2004-11-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
NCT00159770
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
NCT00634348
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
NCT00649064
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT00645229
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
NCT01714011
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ziprasidone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of the recommended daily dose (as delineated by the medication's package insert
Exclusion Criteria
* With antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Alexandria, , Egypt
Pfizer Investigational Site
Asyut, , Egypt
Pfizer Investigational Site
Cairo, , Egypt
Pfizer Investigational Site
Tanta, , Egypt
Pfizer Investigational Site
Larissa, Mezourlo, Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Jordan, , Jordan
Pfizer Investigational Site
Kuwait City, , Kuwait
Pfizer Investigational Site
Beirut, , Lebanon
Pfizer Investigational Site
Khobar, , Saudi Arabia
Pfizer Investigational Site
Garankuwa, Gauteng, South Africa
Pfizer Investigational Site
Krugersdorp, Gauteng, South Africa
Pfizer Investigational Site
Noordheuwel, Krugersdorp, Gauteng, South Africa
Pfizer Investigational Site
Bellair, Durban, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Pinetown, Durban, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Observatory, Cape Town, Western Cape, South Africa
Pfizer Investigational Site
Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Bursa, , Turkey (Türkiye)
Pfizer Investigational Site
Erzurum, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Izmir, , Turkey (Türkiye)
Pfizer Investigational Site
Izmir, , Turkey (Türkiye)
Pfizer Investigational Site
Manisa, , Turkey (Türkiye)
Pfizer Investigational Site
Şişli, , Turkey (Türkiye)
Pfizer Investigational Site
Dubai, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1281117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.